Related Experiment Video
Updated: Jul 16, 2026

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons
Matthew P Mount1, Arman Lira, David Grimes
1Ottawa Health Research Institute, Neuroscience Group, Ottawa, Ontario, Canada K1H 8M5.
Abstract:
Growing evidence implicates microglia in the loss of dopaminergic neurons in Parkinson's disease (PD). However, factors mediating microglial activation in PD are poorly understood. Proinflammatory cytokines, such as interferon-gamma (IFN-gamma), orchestrate the actions of microglia. We report here that PD patients express significantly elevated levels of IFN-gamma in their blood plasma. After this initial finding, we found that IFN-gamma-deficient mice displayed attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced substantia nigra pars compacta dopaminergic cell loss along with reduced loss of striatal tyrosine hydroxylase and dopamine transporter fiber density. MPTP-induced depletion of striatal dopamine and its metabolite DOPAC (3,4-dihydroxyphenylacetic acid), as well as deltaFosB, a marker of postsynaptic dysfunction, were also attenuated in these knock-out mice. Consistent with the role for IFN-gamma in microglial activation, MPTP-induced morphological activation of microglia was abrogated compared with wild-type mice. To examine more mechanistically the role of IFN-gamma in microglial activation, we evaluated the interactions between microglia and dopaminergic neurons in an in vitro mixed microglia/midbrain neuron rotenone-induced death paradigm. In this in vitro paradigm, dopaminergic neurons are selectively damaged by rotenone. Exogenous IFN-gamma ligand alone and without rotenone resulted in dopaminergic cell loss, but only in the presence of microglia. The addition of an IFN-gamma neutralizing antibody attenuated neuronal loss as a result of rotenone treatment. The presence of only wild-type microglia and not those deficient in IFN-gamma receptor elicited significant dopaminergic cell loss when exposed to rotenone. Neurons deficient in IFN-gamma receptor, however, did not display increased resistance to death. Finally, levels of IFN-gamma message increased in microglia in response to rotenone. Together, these data suggest that IFN-gamma participates in death of dopaminergic neurons by regulating microglial activity.
Insights
Interferon-gamma (IFN-gamma) drives microglial activation, contributing to dopaminergic neuron loss in Parkinson's disease. Reducing IFN-gamma levels in patients and mice protects these critical neurons from damage.
Area of Science:
- Neuroscience
- Immunology
- Neurodegenerative Diseases
Background:
- Microglia are implicated in dopaminergic neuron loss in Parkinson's disease (PD).
- The specific factors triggering microglial activation in PD remain unclear.
- Proinflammatory cytokines, like interferon-gamma (IFN-gamma), are known to regulate microglial activity.
Purpose of the Study:
- To investigate the role of interferon-gamma (IFN-gamma) in the pathogenesis of Parkinson's disease.
- To determine if elevated IFN-gamma levels in Parkinson's disease patients contribute to neurodegeneration.
- To elucidate the mechanism by which IFN-gamma influences microglial activation and dopaminergic neuron survival.
Main Methods:
- Measured plasma IFN-gamma levels in Parkinson's disease patients.
- Utilized interferon-gamma-deficient mice in MPTP and rotenone models of Parkinson's disease.
- Assessed dopaminergic neuron loss, fiber density, dopamine levels, and microglial activation in vivo and in vitro.
Main Results:
- Parkinson's disease patients exhibited significantly elevated blood plasma IFN-gamma levels.
- IFN-gamma-deficient mice showed reduced dopaminergic neuron loss and neurochemical deficits in MPTP models.
- In vitro studies demonstrated that IFN-gamma mediates rotenone-induced dopaminergic neuron death via microglial activation.
Conclusions:
- Elevated IFN-gamma in Parkinson's disease patients suggests a role in disease progression.
- IFN-gamma is a critical mediator of microglial activation and subsequent dopaminergic neurodegeneration.
- Targeting IFN-gamma may offer a therapeutic strategy for Parkinson's disease.
